Immune Checkpoint Blockade in NSCLC: Expert Perspectives on Current Standards and the Next Frontier

Sunday, June 3, 2018-Join us for this dynamic CME-certified satellite symposium at ASCO 2018! Expert faculty will provide their insights on the optimal use of immune checkpoint inhibitors and how emerging data may have an impact on the current treatment paradigms.

Register now!

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

Radisson Blu Aqua Hotel

Route 11 - Gate 31: East Bldg, Level 2, near Arie Crown Theater Box Office
One-way travel time is approximately 12-15 minutes.


6:30 PM - 7:00 PM Dinner and Registration

7:00 PM - 7:05 PM Welcome and Overview

7:05 PM - 7:20 PM Histology Agnostic First-Line Immunotherapy for Advanced NSCLC

7:20 PM - 7:35 PM Histology-Specific First-Line Immunotherapy for Advanced NSCLC

7:35 PM - 7:45 PM Panel Discussion with Audience Q&A

7:45 PM - 8:05 PM Immunotherapy for Progressive Metastatic NSCLC

8:05 PM - 8:20 PM Immunotherapy for Locally Advanced and Earlier Stages of NSCLC

8:20 PM - 8:35 PM Clinical Pearls: Immunotherapy in Practice

8:35 PM - 8:55 PM Panel Discussion with Audience Q&A

8:55 PM - 9:00 OM Final Thoughts


Date / Time
Event Details


Program Chair
H. Jack West, MD

Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
Seattle, Washington

Joshua Bauml, MD

Assistant Professor of Medicine 
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Stephen Liu, MD

Associate Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Heather Wakelee, MD

Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University/Stanford Cancer Institute
Stanford, California

Helena A. Yu, MD

Assistant Attending 
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve participants’ competence in optimally applying immune checkpoint inhibitor therapy to improve outcomes for patients with non-small-cell lung cancer.

Target Audience 
This program is intended for physicians and other healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives

  • Plan treatment strategies for patients with NSCLC and disease progression on or after platinum-containing chemotherapy based on available data, treatment guidelines, and expert recommendations
  • Evaluate the therapeutic impact of immune checkpoint inhibitors as a first-line treatment option for patients with advanced NSCLC and high PD-L1 expression
  • Use available biomarkers of response to identify patients with advanced NSCLC who may benefit from immune checkpoint inhibitor therapy
  • Manage immune-related adverse events in patients with advanced NSCLC on checkpoint inhibitor therapy
  • Incorporate investigational checkpoint inhibitors and clinical trial participation as part of clinical care strategies for NSCLC
  • Describe the role of combination approaches to optimize checkpoint inhibitor efficacy and reduce treatment resistance
  • Evaluate the available clinical data and biologic rationale for using immune checkpoint inhibitors in patients with locally advanced NSCLC


Physicians Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.